Last Updated 08:00:00
Zai Lab's commercialization and licensing model in China has seen multiple products included in the national reimbursement drug list (NRDL), with high visibility for revenue growth in 2026.
JD Health, ...
$Beigene(ONC.US)$Zai Lab(ZLAB.US)Trump administration plans to impose strict controls on Chinese pharmaceuticals
mp.weixin.qq.com/s/gihUP-...
Hot Trades in Hong Kong Stocks (8.8)｜Gold Sector Rises Across the Board on Tariff Catalysts, SMIC Leads Decline by 6%
The US imposed a 39% tariff on imported gold bars, sparking a rally in gold stocks, with Lao Feng Xiang rising nearly 4% again. The semiconductor sector was dragged down by SMIC's Q2 net profit plungi...